Novo Nordisk's Ozempic Gets Canada Approval for Kidney Disease

Author: Addison Perry Updated: 08-19-2025 01:44 PM

Novo Nordisk's Ozempic Approved in Canada

In an exciting development for those managing type 2 diabetes, Health Canada has approved Novo Nordisk's Ozempic (semaglutide) specifically to reduce the risk of kidney disease and cardiovascular death. This marks a significant milestone, making Ozempic the first of its kind—an innovative once-weekly treatment that not only enhances glycemic control but also actively lowers the risks associated with kidney function deterioration and heart complications.

The Impact of the FLOW Trial

The approval was heavily supported by outcomes from the FLOW trial, which evaluated the effects of semaglutide on kidney protection in patients diagnosed with type 2 diabetes and chronic kidney disease (CKD). The trial involved over 3,500 participants from various regions, including Canada, showcasing the extensive reach and beneficial implications of this treatment.

Effective Results from Research

The results from the FLOW trial were compelling. Specifically, semaglutide dosed at 1 mg reduced the risk of both kidney disease progression and associated mortality by an impressive 24% compared to a placebo. This critical finding emphasizes the medication's importance in safeguarding kidney health, especially for those at higher risk of deterioration.

Further Approvals for Novo Nordisk

In addition, the U.S. FDA has also granted another approval for Novo Nordisk's Wegovy (semaglutide 2.4 mg), which is aimed at treating noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults who are battling moderate to advanced liver fibrosis. The positive results from the ESSENCE trial have played a significant role in this approval.

Collaboration with GoodRx

On the pricing front, GoodRx has announced a beneficial partnership with Novo Nordisk, allowing eligible self-paying patients access to Ozempic and Wegovy pens at an affordable price of $499 monthly. This initiative has been particularly noteworthy, with around 17 million users seeking GLP-1 medication savings and information through GoodRx last year, reflecting a growing demand for these treatments.

Current Market Response

In light of these developments, Novo Nordisk's stock has shown positive movement, rising by 1.1% to reach $54.34 recently. This uptick indicates strong market support following the favorable approval news and demonstrates the company's commitment to addressing health needs through effective treatments.

Frequently Asked Questions

What is Ozempic used for?

Ozempic is primarily used to manage type 2 diabetes, helping to control blood sugar levels while also reducing the risk of kidney disease and cardiovascular issues.

How does Ozempic work?

Ozempic works by mimicking the effects of incretin, a hormone that increases insulin secretion in response to meals, thus aiding in glucose control.

What were the results of the FLOW trial?

The FLOW trial found that semaglutide significantly reduced the progression of kidney disease and cardiovascular mortality by 24% compared to placebo.

What is the significance of the GoodRx partnership?

The partnership allows eligible patients to access Ozempic and Wegovy pens at a reduced cost of $499 monthly, improving affordability for many individuals seeking these medications.

How has the market responded to these approvals?

Stocks for Novo Nordisk have seen a positive response, with recent increases reflecting investor confidence following the approval announcements for Ozempic and Wegovy.

About The Author

Hello, I'm 30-year-old financial writer and expert Addison Perry, and I love to simplify the intricacies of the financial industry. I've committed myself over the years to deciphering the subtleties of investing techniques and economic trends and converting them into doable guidance that anybody can use. My goal with writings and books is to make money interesting and approachable so that readers may take charge of their financial futures.

My enthusiasm to empowerment and education has propelled me through my career in finance. I write because I think that everyone should be able to make educated financial decisions, and I try to provide that. Regardless of experience level with investing, my work is intended to provide insightful analysis and practical advice to enable you to thrive in the always changing financial environment. I appreciate you traveling with me toward success and financial literacy.

Contact Addison Perry privately here. Or send an email with ATTN: Addison Perry as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.